PharmaTech
DECEMBER 25, 2024
Revised guidelines published by EMA and HMA update the rules on identification of commercially confidential information and personal data used in marketing authorization applications.
Pharmaceutical Commerce
DECEMBER 25, 2024
The latest in container tech and temperature-monitoring truly powered the content.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaTech
DECEMBER 25, 2024
Results from a Phase IIb study missed the primary endpoint by failing to achieve statistical significance.
PharmExec
DECEMBER 25, 2024
In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses regulatory challenges and opportunities that telehealth companies face in 2025.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Pharmacy Times
DECEMBER 25, 2024
This study evaluated factors affecting the duration of the infusion appointment times for 392 clinical trial patients.
PharmExec
DECEMBER 25, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmacy Times
DECEMBER 25, 2024
Panelists discuss how the main treatment goals for patients with primary biliary cholangitis (PBC) include improving liver biochemistry, preventing disease progression to cirrhosis, managing symptoms, and enhancing overall quality of life through regular monitoring and appropriate therapeutic interventions.
Pharmaceutical Technology
DECEMBER 25, 2024
Glufosfamide is under clinical development by Eleison Pharmaceuticals and currently in Phase III for Metastatic Adenocarcinoma of The Pancreas.
Pharmacy Times
DECEMBER 25, 2024
Panelists discuss how some patients with primary biliary cholangitis (PBC) have an inadequate response to ursodeoxycholic acid and require second-line treatments, with options including obeticholic acid, seladelpar, and elafibranor, which improve bile acid homeostasis and reduce inflammation.
Pharmaceutical Technology
DECEMBER 25, 2024
Dexamethasone sodium phosphate SR is under clinical development by Taiwan Liposome and currently in Phase III for Osteoarthritis Pain.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
DECEMBER 25, 2024
Gecacitinib is a novel inhibitor targeting both JAK and ACVR1.
Pharmaceutical Technology
DECEMBER 25, 2024
Fosravuconazole is under clinical development by Eisai and currently in Phase II for Tinea Pedis (Athlete Foot).
Pharmacy Times
DECEMBER 25, 2024
Proper reporting of errors and near misses helps maintain compliance and improve patient safety.
Pharmaceutical Technology
DECEMBER 25, 2024
EXO-CD24 is under clinical development by Nano24med and currently in Phase II for Acute Respiratory Distress Syndrome.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
DECEMBER 25, 2024
AROC-3 is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for IgA Nephropathy (Berger's Disease).
Pharmaceutical Technology
DECEMBER 25, 2024
Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome.
Pharmaceutical Technology
DECEMBER 25, 2024
Gamma-PN is under clinical development by GPN Vaccines and currently in Phase II for Streptococcal Pneumonia.
Pharmaceutical Technology
DECEMBER 25, 2024
ACTUS-101 is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Pompe Disease.
Pharmaceutical Technology
DECEMBER 25, 2024
NB-4746 is under clinical development by Nura Bio and currently in Phase I for Amyotrophic Lateral Sclerosis.
Expert insights. Personalized for you.
59 
Let's personalize your content